AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26444729 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a (30 μg intramuscularly once weekly)
Number of subjects: 1841
Study 26444729 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP
Number of subjects: 1841
Study 26444729 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 1841
Study 23667440 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based ontology development training
Number of subjects: 24
Study 23667440 — intervention group
Group type: COMPARATOR
Intervention: Basic principles of formal ontology engineering training
Number of subjects: 24
Study 23667440 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential training on topics in ontology development
Number of subjects: 24
Study 21131201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycra(®) splint wear for three months
Number of subjects: 16
Study 21131201 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 16
Study 19752420 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mg intravitreal triamcinolone
Number of subjects: 411
Study 19752420 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg intravitreal triamcinolone
Number of subjects: 411
Study 19752420 — intervention group
Group type: COMPARATOR
Intervention: Standard care (grid photocoagulation)
Number of subjects: 411
Study 16924272 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3.2 g/day for 6 months
Number of subjects: 40
Study 16924272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15049885 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 487
Study 15049885 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg daily
Number of subjects: 487
Study 11715619 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective bowel decontamination with tobramycin, polymyxin B and amphotericin B
Number of subjects: 70
Study 11715619 — intervention group
Group type: COMPARATOR
Intervention: Control group (no selective bowel decontamination)
Number of subjects: 70
Study 12515414 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP step 2 diet
Number of subjects: 364
Study 8048199 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia only (EA, n = 34)
Number of subjects: 98
Study 8048199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia (EG, n = 33)
Number of subjects: 98
Study 8048199 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (GA, n = 31)
Number of subjects: 98
Study 2730822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline 1 in 200,000
Number of subjects: 80
Study 2730822 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 80
Study 1123897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol infusion at 0.125 g/kg/h
Number of subjects: 20
Study 1123897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol infusion at 0.25 g/kg/h
Number of subjects: 20
Study 31003654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation (1:10 ratio of lavender and sweet almond oil)
Number of subjects: 60
Study 31003654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lavender oil inhalation)
Number of subjects: 60
Study 28420673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 30
Study 28420673 — intervention group
Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 30
Study 25486371 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening Visits (LV)
Number of subjects: 66
Study 25486371 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 66
Study 23708942 — intervention group
Group type: EXPERIMENTAL
Intervention: IIH patients
Number of subjects: 21
Study 23708942 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 21870630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet including 30 g day(‐1) of soy protein
Number of subjects: 52
Study 21870630 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-calorie diet without soy protein)
Number of subjects: 52
Study 21870630 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet
Number of subjects: 52
Study 19702850 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri OLL2716 (LG21) containing cheese
Number of subjects: 440
Study 19702850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ordinary cheese)
Number of subjects: 440
Study 16498362 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) such as Anastrozole, Letrozole, and Exemestane
Number of subjects: 0
Study 16498362 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0
Study 12969362 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark implants
Number of subjects: 25
Study 12969362 — intervention group
Group type: COMPARATOR
Intervention: ITI implants
Number of subjects: 25
Study 10714567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (n = 11)
Number of subjects: 21
Study 10714567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 21
Study 9198260 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme
Number of subjects: 0
Study 9198260 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1526392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose in the postprandial period
Number of subjects: 12
Study 1526392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol in the postprandial period
Number of subjects: 12
Study 1526392 — intervention group
Group type: COMPARATOR
Intervention: Lactulose in the fasting state
Number of subjects: 12
Study 1526392 — intervention group
Group type: COMPARATOR
Intervention: Lactitol in the fasting state
Number of subjects: 12
Study 1526392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both disaccharides (lactulose and lactitol)
Number of subjects: 12
Study 3931144 — intervention group
Group type: COMPARATOR
Intervention: 5 mg diazepam
Number of subjects: 36
Study 3931144 — intervention group
Group type: COMPARATOR
Intervention: 10 mg diazepam
Number of subjects: 36
Study 3931144 — intervention group
Group type: COMPARATOR
Intervention: 5 mg d,l-amphetamine
Number of subjects: 36
Study 3931144 — intervention group
Group type: EXPERIMENTAL
Intervention: amphetamine
Number of subjects: 36
Study 30043434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg
Number of subjects: 210
Study 30043434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg/kg
Number of subjects: 210
Study 30043434 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 20 mg/kg
Number of subjects: 210
Study 28394012 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ischemic and non-hypertensive heart failure management
Number of subjects: 5563
Study 28394012 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted CRT-D and ICD
Number of subjects: 5563
Study 28394012 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure of non-ischemic and non-hypertensive origin
Number of subjects: 5563
Study 26987376 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 43
Study 26987376 — intervention group
Group type: COMPARATOR
Intervention: PI/r switching
Number of subjects: 43
Study 24887013 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (2 g daily)
Number of subjects: 59
Study 22346753 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental hookworm infection
Number of subjects: 0
Study 20624140 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg IV followed by 0.5 mg/kg every 3 minutes as needed
Number of subjects: 100
Study 20624140 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 1.0 mg/kg IV followed by 0.5 mg/kg every 3 minutes as needed
Number of subjects: 100
Study 17898702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy (MSCs)
Number of subjects: 29
Study 17898702 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 11814216 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual Distinctiveness (CD)
Number of subjects: 0
Study 11814216 — intervention group
Group type: COMPARATOR
Intervention: Occurrence Frequency
Number of subjects: 0
Study 11814216 — intervention group
Group type: COMPARATOR
Intervention: Concreteness, Context Availability, Number of Contexts, Ambiguity, Age of Acquisition, Familiarity
Number of subjects: 0
Study 9489908 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg twice daily) and Amoxicillin (750 mg three times daily)
Number of subjects: 158
Study 9489908 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg twice daily) and Placebo (750 mg three times daily)
Number of subjects: 158
Study 7917910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum (50 mg m‐2) with ondansetron (8 mg i.v. x 3 at chemotherapy and 8 mg p.o. x 3 for 5 days)
Number of subjects: 62
Study 7917910 — intervention group
Group type: COMPARATOR
Intervention: Low or moderately emetogenic chemotherapy
Number of subjects: 62
Study 3070048 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based health promotion program (1-year intervention)
Number of subjects: 60
Study 3070048 — intervention group
Group type: COMPARATOR
Intervention: Control families
Number of subjects: 60
Study 31648988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell injections (MSCs)
Number of subjects: 34
Study 28514784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (80 mg of rosuvastatin loading followed by 40 mg daily)
Number of subjects: 140
Study 28514784 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy (usual-care group)
Number of subjects: 140
Study 28514784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (in patients with abnormal glucose tolerance)
Number of subjects: 140
Study 28514784 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy (in patients with abnormal glucose tolerance)
Number of subjects: 140
Study 25931419 — intervention group
Group type: EXPERIMENTAL
Intervention: Actazin high dose (Actazin-H) [2400 mg/day]
Number of subjects: 28
Study 25931419 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold [2400 mg/day]
Number of subjects: 28
Study 25931419 — intervention group
Group type: EXPERIMENTAL
Intervention: Actazin low dose (Actazin-L) [600 mg/day]
Number of subjects: 28
Study 25931419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23743088 — intervention group
Group type: EXPERIMENTAL
Intervention: TREAT decision support system for antibiotic treatment (intervention arm)
Number of subjects: 1683
Study 23743088 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 1683
Study 21983496 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 1449
Study 21983496 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytics
Number of subjects: 1449
Study 21983496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative/hypnotics
Number of subjects: 1449
Study 20182958 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Transitions Intervention
Number of subjects: 0
Study 20182958 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 17150155 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal models of AAA
Number of subjects: 0
Study 15293891 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (Conjugated Estrogen)
Number of subjects: 150
Study 15293891 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA (Conjugated Estrogen + Medroxyprogesterone Acetate)
Number of subjects: 150
Study 15293891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 150
Study 11203790 — intervention group
Group type: EXPERIMENTAL
Intervention: Silux Plus
Number of subjects: 60
Study 11203790 — intervention group
Group type: COMPARATOR
Intervention: Z100
Number of subjects: 60
Study 9133173 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of plain 0.5% bupivacaine and hyperbaric 4% mepivacaine
Number of subjects: 122
Study 9133173 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric 0.5% bupivacaine
Number of subjects: 122
Study 8380291 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 67
Study 8380291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30850896 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 20
Study 30850896 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 20
Study 28475816 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant human IL-1 receptor antagonist)
Number of subjects: 0
Study 28475816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26620271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary wedge resection plus parietal pleurectomy (WRPP)
Number of subjects: 360
Study 26620271 — intervention group
Group type: COMPARATOR
Intervention: Parietal pleurectomy (PP)
Number of subjects: 360
Study 23647728 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-factor model of PTSD
Number of subjects: 151
Study 23647728 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-factor dysphoria model
Number of subjects: 151
Study 23647728 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-factor emotional numbing model
Number of subjects: 151
Study 23647728 — intervention group
Group type: COMPARATOR
Intervention: 3-factor model of PTSD
Number of subjects: 151
Study 21132451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/PEG-IFN group
Number of subjects: 50
Study 21132451 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/IFN group
Number of subjects: 50
Study 21132451 — intervention group
Group type: COMPARATOR
Intervention: CDDP group
Number of subjects: 50
Study 18206361 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC 250/50 mcg once daily
Number of subjects: 844
Study 18206361 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 250 mcg once daily
Number of subjects: 844
Study 18206361 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC 100/50 mcg twice daily
Number of subjects: 844
Study 18206361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 844
Study 16529615 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg bid, titrated to 1,000 mg bid
Number of subjects: 25
Study 16529615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15470802 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine + Lamotrigine
Number of subjects: 40
Study 15470802 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine + Placebo
Number of subjects: 40
Study 11299228 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg once daily)
Number of subjects: 27
Study 11299228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11299228 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan and Placebo
Number of subjects: 27
Study 9303380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg once daily on days 16-30)
Number of subjects: 13
Study 9303380 — intervention group
Group type: COMPARATOR
Intervention: Delavirdine mesylate (300 mg every 8 hours for 30 days)
Number of subjects: 13
Study 8417428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/day daily)
Number of subjects: 108
Study 8417428 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg/day divided into two doses)
Number of subjects: 108
Study 8417428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 108
Study 8417428 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 108
Study 3752963 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3 (biological response modifier) with adjuvant radiotherapy and chemotherapy
Number of subjects: 46
Study 3752963 — intervention group
Group type: COMPARATOR
Intervention: Control group (adjuvant radiotherapy and chemotherapy without AM3)
Number of subjects: 46
Study 29943350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor (N=696)
Number of subjects: 2099
Study 29943350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (N=706)
Number of subjects: 2099
Study 29943350 — intervention group
Group type: COMPARATOR
Intervention: Warfarin plus DAPT (N=697)
Number of subjects: 2099
Study 25871479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery at 1667 m
Number of subjects: 12
Study 25871479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery at 3333 m
Number of subjects: 12
Study 25871479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery at 5000 m
Number of subjects: 12
Study 25871479 — intervention group
Group type: COMPARATOR
Intervention: Recovery at 0 m
Number of subjects: 12
Study 25130629 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplement (Nutrisen) with increased whey protein (200 ml daily for 8 weeks)
Number of subjects: 47
Study 25130629 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutritional supplement (Nutrisen)
Number of subjects: 47
Study 22260233 — intervention group
Group type: EXPERIMENTAL
Intervention: baby wipes
Number of subjects: 44
Study 22260233 — intervention group
Group type: COMPARATOR
Intervention: water-moistened washcloth
Number of subjects: 44
Study 20937162 — intervention group
Group type: EXPERIMENTAL
Intervention: C. longa (6 g)
Number of subjects: 14
Study 20937162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18782799 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with low-dosage Mitomycin-C (MMC) (0.2 mg/ml, 2 min application)
Number of subjects: 114
Study 18782799 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with low-dosage Mitomycin-C (MMC)
Number of subjects: 114
Study 18782799 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with balanced saline solution (BSS)
Number of subjects: 114
Study 16038912 — intervention group
Group type: EXPERIMENTAL
Intervention: TO+++ (therapeutic objective attained in all 3 years, n=145)
Number of subjects: 579
Study 16038912 — intervention group
Group type: EXPERIMENTAL
Intervention: TO intermediate (therapeutic objective attained only part of the time, n=256)
Number of subjects: 579
Study 16038912 — intervention group
Group type: EXPERIMENTAL
Intervention: TO--- (therapeutic objective never attained, n=178)
Number of subjects: 579
Study 12528105 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (MTX)
Number of subjects: 40
Study 12528105 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and intraarticular corticosteroids (MTX + IAST)
Number of subjects: 40
Study 12528105 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (after 3 months for both groups)
Number of subjects: 40
Study 10494965 — intervention group
Group type: EXPERIMENTAL
Intervention: New split influenza vaccine derived from BV-5F1 cell line
Number of subjects: 0
Study 10494965 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8558199 — intervention group
Group type: EXPERIMENTAL
Intervention: N4-behenoyl-1-beta-D-arabinosylcytosine (BHAC)
Number of subjects: 326
Study 8558199 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine
Number of subjects: 326
Study 8558199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubenimex
Number of subjects: 326
Study 8558199 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 326
Study 1878535 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 10 mg
Number of subjects: 8
Study 1878535 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 8
Study 1878535 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (various doses)
Number of subjects: 8
Study 6415780 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg every 12 hr for five days)
Number of subjects: 8721
Study 6415780 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 8721
Study 6415780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 8721
Study 6415780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8721
Study 6415780 — intervention group
Group type: EXPERIMENTAL
Intervention: Second cycle of minocycline followed by group C polysaccharide vaccine
Number of subjects: 8721
Study 30462830 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab treatment
Number of subjects: 1434
Study 29907485 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV (measles-containing vaccine)
Number of subjects: 684
Study 29907485 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV2 (second dose of measles-containing vaccine)
Number of subjects: 684
Study 27631634 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural (EP) administration of ropivacaine every 6 hours
Number of subjects: 18
Study 27631634 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion (SC) of ropivacaine after a bolus dose for 48 hours
Number of subjects: 18
Study 25430900 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/Brimonidine 0.2% (BBFC)
Number of subjects: 0
Study 25430900 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide 1% plus Brimonidine 0.2% (BRINZ + BRIM)
Number of subjects: 0
Study 25430900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BBFC and BRINZ + BRIM
Number of subjects: 0
Study 22616930 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair with P90 System Adhesive Self‐Etch Primer and Bond and Filtek P90 Low Shrink Posterior Restorative
Number of subjects: 100
Study 22616930 — intervention group
Group type: COMPARATOR
Intervention: Repair with Adper SE Plus and Filtek P60 Posterior Restorative
Number of subjects: 100
Study 19829110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (TGC)
Number of subjects: 3
Study 19829110 — intervention group
Group type: COMPARATOR
Intervention: Control of cardiovascular risk factors
Number of subjects: 3